文献速递甲状腺疾病

老年亚临床甲状腺功能减退症患者甲状腺激素替代治疗的患者报告满意度:两项随机对照试验个体参与者数据的汇总分析

Patient-Reported Satisfaction with Thyroid Hormone Replacement Therapy for Subclinical Hypothyroidism in Older Adults: A Pooled Analysis of Individual Participant Data from Two Randomized Controlled Trials.
PubMed 文献 · Thyroid · 2024-05-03

本研究汇总分析了两项随机双盲安慰剂对照试验的个体数据,比较老年亚临床甲状腺功能减退症患者使用左甲状腺素或安慰剂的治疗满意度。共纳入536名≥65岁参与者,结果显示两组在总体满意度及各领域均无显著差异,仅在基线症状负担高的亚组中左甲状腺素组更常希望继续用药。作者认为该结果支持不常规处方左甲状腺素。

要点

  • 老年亚临床甲减患者中,左甲状腺素与安慰剂在治疗满意度各领域均无显著差异。
  • 基线促甲状腺激素水平或症状负担不影响满意度结果。
  • 基线症状负担高的亚组中,左甲状腺素组更常希望继续用药。

核心结论

  • 两项随机对照试验的汇总数据显示,老年亚临床甲状腺功能减退症患者接受左甲状腺素或安慰剂的治疗满意度无 major 差异,作者认为该发现对启动左甲状腺素治疗的决策有重要意义,并总体上支持不常规处方左甲状腺素。

研究设计与样本

  • 汇总分析了两项随机双盲安慰剂对照试验的个体参与者数据,纳入社区居住的≥65岁、持续性促甲状腺激素水平4.60-19.99 mIU/L持续>3个月且游离T4正常的亚临床甲状腺功能减退症患者,共536人。

主要发现

  • 基线中位(四分位距)年龄为74.9(69.7-81.4)岁,292人(55%)为女性。
  • 基线时两组中位(四分位距)促甲状腺激素水平均为5.80(5.10-7.00)mIU/L;末次访视时安慰剂组为4.97(3.90-6.35)mIU/L,左甲状腺素组为3.24(2.49-4.41)mIU/L。
  • 无论基线促甲状腺激素水平或症状负担如何,上述结果一致。
  • 试验后希望继续用药的人数无 major 差异:左甲状腺素组35% vs 安慰剂组27%;不希望继续者左甲状腺素组27% vs 安慰剂组30%;不知道者左甲状腺素组37% vs 安慰剂组42%(p=0.14)。

临床怎么用

  • 作者认为,这些发现总体上支持在老年亚临床甲状腺功能减退症患者中不常规处方左甲状腺素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The benefit of levothyroxine treatment of subclinical hypothyroidism (SCH) is subject to debate. This study compared treatment satisfaction between older adults with SCH using levothyroxine or placebo. Methods: We analyzed pooled individual participant data from two randomized, double-blind, placebo-controlled trials investigating the effects of levothyroxine treatment in older adults with SCH. Community-dwelling participants aged ≥65 years, with SCH (persistent thyrotropin levels 4.60-19.99 mIU/L for >3 months and normal free T4 level), were included. Intervention dose titration until thyrotropin levels normalized, with a mock dose adjustment of placebo. Treatment satisfaction was determined during the final study visit using the Treatment Satisfaction Questionnaire for Medication (TSQM), encompassing perceived effectiveness, side effects, convenience, and global satisfaction, along with the participants' desire to continue study medication after the trial. Results: We included 536 participants. At baseline, the median (interquartile range [IQR]) age was 74.9 (69.7-81.4) years, and 292 (55%) were women. The median (IQR) thyrotropin levels were 5.80 (5.10-7.00) mIU/L at baseline in both groups; at final visit, 4.97 (3.90-6.35) mIU/L in the placebo and 3.24 (2.49-4.41) mIU/L in the levothyroxine group. After treatment, the groups did not differ significantly in global satisfaction (mean difference [CI] -1.1 [-4.5 to 2.1], p = 0.48), nor in any other domain of treatment satisfaction. These results held true regardless of baseline thyrotropin levels or symptom burden. No major differences were found in the numbers of participants who wished to continue medication after the trial (levothyroxine 35% vs. placebo 27%), did not wish to continue (levothyroxine 27% vs. placebo 30%), or did not know (levothyroxine 37% vs. placebo 42%) (p = 0.14). In a subpopulation with high symptom burden from hypothyroid symptoms at baseline, those using levothyroxine more often desired to continue the medication after the trial than those using placebo (mean difference [CI]: -21.1% [-35.6% to -6.5%]). Conclusion: These pooled data from two RCTs showed no major differences in treatment satisfaction between older adults receiving levothyroxine or placebo. This finding has important implications for decision-making regarding initiating levothyroxine treatment for SCH. Our findings generally support refraining from routinely prescribing levothyroxine in older adults with SCH.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Ravensberg J, Poortvliet RKE, Du Puy R, et al. Patient-Reported Satisfaction with Thyroid Hormone Replacement Therapy for Subclinical Hypothyroidism in Older Adults: A Pooled Analysis of Individual Participant Data from Two Randomized Controlled Trials. Thyroid. 2024. PMID: 38661527. doi:10.1089/thy.2023.0624

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。